KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 113 filers reported holding KALVISTA PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $23,312,795 | +27.3% | 2,420,851 | +19.0% | 1.26% | +28.7% |
Q2 2023 | $18,310,554 | +17.5% | 2,034,506 | +2.6% | 0.98% | +48.8% |
Q1 2023 | $15,587,787 | +115.0% | 1,983,179 | +84.9% | 0.66% | +116.4% |
Q4 2022 | $7,248,762 | -70.7% | 1,072,302 | -37.2% | 0.30% | -70.5% |
Q3 2022 | $24,770,000 | +30.6% | 1,707,100 | -11.5% | 1.03% | +42.7% |
Q2 2022 | $18,973,000 | -26.3% | 1,928,200 | +10.4% | 0.72% | -8.3% |
Q1 2022 | $25,740,000 | +11.4% | 1,746,300 | 0.0% | 0.79% | +75.8% |
Q4 2021 | $23,104,000 | -14.2% | 1,746,300 | +13.2% | 0.45% | -1.5% |
Q3 2021 | $26,930,000 | -5.6% | 1,543,284 | +29.6% | 0.45% | +6.3% |
Q2 2021 | $28,539,000 | +15.7% | 1,191,101 | +24.1% | 0.43% | +17.0% |
Q1 2021 | $24,660,000 | +320.4% | 959,892 | +210.7% | 0.36% | +334.5% |
Q4 2020 | $5,866,000 | +50.8% | 308,900 | 0.0% | 0.08% | +20.0% |
Q3 2020 | $3,889,000 | +30.1% | 308,900 | +25.1% | 0.07% | +9.4% |
Q2 2020 | $2,989,000 | +242.0% | 247,000 | +116.3% | 0.06% | +166.7% |
Q1 2020 | $874,000 | – | 114,200 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SV Health Investors, LLC | 1,719,576 | $25,679,000 | 12.37% |
Vivo Capital, LLC | 1,618,296 | $30,731,000 | 1.37% |
Opaleye Management Inc. | 470,203 | $8,929,000 | 1.17% |
INTERWEST VENTURE MANAGEMENT CO | 388,766 | $7,383,000 | 0.92% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 177,433 | $3,369,000 | 0.92% |
Ikarian Capital, LLC | 1,063,961 | $20,204,000 | 0.89% |
Ghost Tree Capital, LLC | 200,000 | $3,798,000 | 0.85% |
Logos Global Management LP | 490,000 | $9,305,000 | 0.80% |
Eventide Asset Management | 1,680,000 | $31,903,000 | 0.49% |
Affinity Asset Advisors, LLC | 45,000 | $855,000 | 0.45% |